MCID: CLR108
MIFTS: 64

Colorectal Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenoma

MalaCards integrated aliases for Colorectal Adenoma:

Name: Colorectal Adenoma 12 29 6 15 17
Adenoma of Large Intestine 71
Colorectal Adenomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0050860
UMLS 71 C1302401

Summaries for Colorectal Adenoma

Disease Ontology : 12 An intestinal benign neoplasm that has material basis in epithelial tissue of glandular origin and is located in colon and located in rectum.

MalaCards based summary : Colorectal Adenoma, also known as adenoma of large intestine, is related to mismatch repair cancer syndrome and polyposis syndrome, hereditary mixed, 1. An important gene associated with Colorectal Adenoma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are ERK Signaling and fMLP Pathway. The drugs Anesthetics and Calcium carbonate have been mentioned in the context of this disorder. Affiliated tissues include colon, rectum and testes, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 74 The colorectal adenoma is a benign glandular tumor of the colon and the rectum. It is a precursor lesion... more...

Related Diseases for Colorectal Adenoma

Diseases related to Colorectal Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 450)
# Related Disease Score Top Affiliating Genes
1 mismatch repair cancer syndrome 33.5 MSH2 MLH1 CTNNB1 APC
2 polyposis syndrome, hereditary mixed, 1 33.5 PTGS2 ODC1 MUTYH MSH2 MLH1 GREM1
3 myh-associated polyposis 33.1 MUTYH MSH2 KRAS HRAS APC
4 adenoma 32.1 TP53 PTGS2 ODC1 MUTYH MSH2 MLH1
5 villous adenoma 31.4 TP53 MLH1 KRAS HRAS APC
6 colon adenoma 31.4 VDR MIR15A KRAS APC
7 attenuated familial adenomatous polyposis 31.4 MUTYH MSH2 APC
8 adenocarcinoma 31.1 TP53 PTGS2 MYC MSH2 MLH1 KRAS
9 in situ carcinoma 30.8 TP53 MYC MIR17 HRAS CTNNB1 CDH1
10 familial adenomatous polyposis 30.8 TP53 PTGS2 ODC1 MYC MUTYH MSH2
11 colitis 30.7 PTGS2 MSH2 MLH1 CTNNB1
12 gastritis 30.7 TP53 PTGS2 ODC1 CDH1
13 hyperplastic polyposis syndrome 30.7 TP53 MUTYH KRAS APC
14 colorectal adenocarcinoma 30.7 TP53 PTGS2 MYC MSH2 MLH1 KRAS
15 atrophic gastritis 30.6 TP53 PTGS2 ODC1
16 familial colorectal cancer 30.6 MUTYH MSH2 MLH1 CDH1 APC
17 microinvasive gastric cancer 30.6 TP53 MLH1 CDH1
18 mucinous adenocarcinoma 30.6 TP53 MLH1 KRAS
19 peutz-jeghers syndrome 30.5 TP53 CTNNB1 APC
20 hepatoblastoma 30.5 TP53 MYC CTNNB1 APC
21 peptic ulcer disease 30.5 TP53 PTGS2 HRAS
22 ascending colon cancer 30.4 MSH2 MLH1 KRAS HRAS
23 basal cell carcinoma 30.4 VDR TP53 PTGS2 CTNNB1 CDH1
24 diabetes mellitus 30.4 VDR TP53 PTGS2 MTHFR MIR17 IGFBP3
25 juvenile polyposis syndrome 30.4 PTGS2 MUTYH MSH2 MLH1 GREM1 APC
26 appendix adenocarcinoma 30.3 KRAS HRAS
27 tubular adenocarcinoma 30.3 MIR21 CTNNB1 CDH1
28 meningioma, familial 30.3 TP53 MYC IGF1 CTNNB1 CDH1
29 lynch syndrome 30.1 TP53 MUTYH MTHFR MSH2 MLH1 MIR17
30 barrett esophagus 30.1 TP53 PTGS2 ODC1 MYC CTNNB1 CDH1
31 hepatitis b 30.0 TP53 MYC MIR21 MIR17 KRAS
32 body mass index quantitative trait locus 11 30.0 TP53 PTGS2 MIR21 MIR17 IGFBP3 IGF1
33 osteoporosis 30.0 VDR TP53 PTGS2 MTHFR MIR21 IGFBP3
34 rectum cancer 30.0 VDR MUTYH MSH2 MLH1 MIR21 MIR17
35 gallbladder disease 29.9 TP53 MIR17 KRAS HRAS CTNNB1 CDH1
36 inflammatory bowel disease 29.9 VDR TP53 PTGS2 MYC MTHFR MLH1
37 gastric adenocarcinoma 29.7 TP53 PTGS2 ODC1 MYC MLH1 KRAS
38 li-fraumeni syndrome 29.7 TP53 MYC MUTYH MSH2 MLH1 KRAS
39 endometrial cancer 29.6 TP53 MYC MUTYH MSH2 MLH1 KRAS
40 diabetes mellitus, noninsulin-dependent 29.5 VDR TP53 PTGS2 MTHFR MIR21 MIR17
41 colon adenocarcinoma 29.5 TP53 PTGS2 ODC1 MYC MLH1 MIR21
42 skin carcinoma 29.5 VDR TP53 PTGS2 ODC1 MSH2 MIR21
43 b-cell lymphoma 29.4 TP53 MYC MIR21 MIR17 MIR15A
44 medulloblastoma 29.2 TP53 PTGS2 ODC1 MYC MSH2 MIR17
45 colorectal cancer 28.9 VDR TP53 PTGS2 ODC1 MYC MUTYH
46 ovarian cancer 28.9 TP53 PTGS2 MYC MSH2 MLH1 MIR21
47 esophageal cancer 28.8 TP53 PTGS2 MYC MTHFR MSH2 MLH1
48 gastrointestinal system disease 28.7 MIR21 MIR17 MIR15A APC
49 myeloma, multiple 28.7 TP53 MYC MIR21 MIR17 MIR15A KRAS
50 breast cancer 28.5 VDR TP53 PTGS2 ODC1 MYC MTHFR

Graphical network of the top 20 diseases related to Colorectal Adenoma:



Diseases related to Colorectal Adenoma

Symptoms & Phenotypes for Colorectal Adenoma

GenomeRNAi Phenotypes related to Colorectal Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CDH1 HRAS IGF1 IGFBP3 KRAS MUTYH

MGI Mouse Phenotypes related to Colorectal Adenoma:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 APC CDH1 CTNNB1 GREM1 IGF1 IGFBP3
2 homeostasis/metabolism MP:0005376 10.46 APC CDH1 CTNNB1 GREM1 HRAS IGF1
3 growth/size/body region MP:0005378 10.42 APC CDH1 CTNNB1 GREM1 HRAS IGF1
4 mortality/aging MP:0010768 10.4 APC CDH1 CTNNB1 GREM1 HRAS IGF1
5 integument MP:0010771 10.38 APC CDH1 CTNNB1 HRAS IGF1 IGFBP3
6 cardiovascular system MP:0005385 10.36 APC CDH1 CTNNB1 HRAS IGF1 IGFBP3
7 endocrine/exocrine gland MP:0005379 10.36 APC CDH1 CTNNB1 HRAS IGF1 IGFBP3
8 digestive/alimentary MP:0005381 10.34 APC CDH1 CTNNB1 HRAS KRAS MLH1
9 immune system MP:0005387 10.29 APC CDH1 CTNNB1 IGF1 KRAS MLH1
10 nervous system MP:0003631 10.28 APC CTNNB1 GREM1 HRAS IGF1 IGFBP3
11 embryo MP:0005380 10.24 APC CDH1 CTNNB1 GREM1 KRAS MYC
12 neoplasm MP:0002006 10.23 APC CDH1 CTNNB1 HRAS IGF1 KRAS
13 limbs/digits/tail MP:0005371 10.22 APC CTNNB1 GREM1 IGF1 IGFBP3 KRAS
14 adipose tissue MP:0005375 10.17 APC IGF1 IGFBP3 MYC ODC1 PTGS2
15 craniofacial MP:0005382 10.15 APC CTNNB1 HRAS KRAS MYC TP53
16 muscle MP:0005369 10.13 APC CTNNB1 IGF1 IGFBP3 KRAS MYC
17 hearing/vestibular/ear MP:0005377 10.11 APC CTNNB1 IGF1 KRAS MYC TP53
18 liver/biliary system MP:0005370 10.11 APC CTNNB1 IGFBP3 KRAS MTHFR MYC
19 normal MP:0002873 10.07 APC CDH1 CTNNB1 HRAS IGF1 KRAS
20 no phenotypic analysis MP:0003012 10.01 CDH1 CTNNB1 HRAS KRAS MTHFR MYC
21 reproductive system MP:0005389 9.93 APC CDH1 CTNNB1 GREM1 IGF1 KRAS
22 renal/urinary system MP:0005367 9.91 APC CTNNB1 GREM1 HRAS IGF1 KRAS
23 pigmentation MP:0001186 9.8 APC CTNNB1 IGFBP3 KRAS MYC TP53
24 respiratory system MP:0005388 9.56 CTNNB1 GREM1 HRAS IGF1 KRAS MLH1
25 skeleton MP:0005390 9.4 APC CTNNB1 GREM1 HRAS IGF1 IGFBP3

Drugs & Therapeutics for Colorectal Adenoma

Drugs for Colorectal Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anesthetics Phase 4
2
Calcium carbonate Approved, Investigational Phase 3 471-34-1
3
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
4
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
5
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
6
Zinc Approved, Investigational Phase 3 7440-66-6 32051
7
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
8
Calcitriol Approved, Nutraceutical Phase 3 32222-06-3 5280453 134070
9
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
11
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
12 Tocotrienol Investigational Phase 3 6829-55-6
13 Hematinics Phase 2, Phase 3
14 Omega 3 Fatty Acid Phase 2, Phase 3
15 Analgesics Phase 3
16 Analgesics, Non-Narcotic Phase 3
17 Cyclooxygenase Inhibitors Phase 3
18 Anti-Inflammatory Agents Phase 3
19 Antirheumatic Agents Phase 3
20 Anti-Inflammatory Agents, Non-Steroidal Phase 3
21 Acetylsalicylic acid lysinate Phase 3
22 Vitamins Phase 3
23 Calcium, Dietary Phase 3
24 Calciferol Phase 3
25 Micronutrients Phase 3
26 Trace Elements Phase 3
27 Nutrients Phase 3
28 Cola Phase 3
29 Fibrinolytic Agents Phase 3
30 Antipyretics Phase 3
31 Platelet Aggregation Inhibitors Phase 3
32 Hormones Phase 3
33 Vasoconstrictor Agents Phase 3
34 Dihydroxycholecalciferols Phase 3
35 Hypolipidemic Agents Phase 3
36 Lipid Regulating Agents Phase 3
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
38 Anticholesteremic Agents Phase 3
39 Antimetabolites Phase 3
40 Antioxidants Phase 3
41 Tocopherols Phase 3
42 Tocotrienols Phase 3
43 Protective Agents Phase 3
44 Rosuvastatin Calcium Phase 3 147098-20-2
45 Retinol palmitate Phase 3
46 retinol Phase 3
47
Calcium Nutraceutical Phase 3 7440-70-2 271
48
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
49
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
50
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
2 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Suspended NCT01023984 Phase 4
3 Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial Unknown status NCT02143505 Phase 2, Phase 3 Ca plus vit D
4 A Randomize Controlled Trial of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer Unknown status NCT02066688 Phase 2, Phase 3 folic acid;folic acid calcium vitamin D3;calcium
5 A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas Completed NCT02226185 Phase 2, Phase 3 Berberine hydrochloride;placebo
6 A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas Completed NCT00282386 Phase 3 MK0966; Rofecoxib / Duration of Treatment: 156 weeks;Placebo/ Duration of Treatment: 156 weeks
7 Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) Completed NCT00141193 Phase 3 Celecoxib
8 S0000D: A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT Completed NCT00706121 Phase 3 Vitamin E;Selenium;Vitamin E placebo;selenium placebo
9 Prevention of Sporadic Colorectal Adenomas With Celecoxib Completed NCT00005094 Phase 3 celecoxib
10 Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study Completed NCT00002527 Phase 3 aspirin
11 A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid Completed NCT00510692 Phase 2, Phase 3 Eicosapentanoic Acid (EPA);Placebo
12 Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Recruiting NCT02813824 Phase 3 Acetylsalicylic acid lysinate 300 mg;Placebo (for Aspirin 300);Acetylsalicylic acid lysinate 100 mg;Placebo 100 (for Aspirin 100)
13 A Randomized Trial of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer Recruiting NCT03281096 Phase 2, Phase 3 Berberine hydrochloride;Placebo
14 The Effect of Berberine Hydrochloride in Familial Adenomatous Polyposis:a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial Recruiting NCT03333265 Phase 2, Phase 3 100mg Berberine hydrochloride;300mg Berberine hydrochloride;Placebo Oral Tablet
15 Enteric-coated Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients (the APREMEC Trial): a Large-scale Multicenter Randomized Double-blind Placebo-controlled Trial Recruiting NCT02607072 Phase 3 Acetylsalicylic acid (ASA)/aspirin 200 mg daily;Acetylsalicylic acid (ASA)/aspirin 100 mg daily;Placebo
16 A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas Terminated NCT00486512 Phase 3 aspirin, 1,25-dihydroxycholecalciferol, calcium;placebo
17 Statin Polyp Prevention Trial in Patients With Resected Colon Cancer Terminated NCT01011478 Phase 3 rosuvastatin
18 Evaluation of the Efficacy of a Combination of Micronutrients (Vitamin A, C, E, Selenium and Zinc) in Reducing the Incidence of Colorectal Metachronous Adenomas. A Double Blind, Phase III, Randomized, Placebo-controlled Trial Terminated NCT01437826 Phase 3 antioxidants;placebo
19 Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence Terminated NCT00224679 Phase 3 Aspirin
20 3389 Colorectal Adenoma: Chemoprevention With Folic Acid Completed NCT00018551 Phase 2 Folic Acid
21 Chemopreventive Effects of Mesalazine in Patients at High Risk of Recurrent (Nonfamilial) Colorectal Adenomas Completed NCT01894685 Phase 2 Mesalazine;Placebo
22 Randomized, Placebo-Controlled, Phase 2B Evaluation of Cyclooxygenase-2 Activity in Surgically Resected Primary Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
23 A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index Completed NCT01312467 Phase 2 metformin hydrochloride
24 Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE- Completed NCT01360320 Phase 2
25 Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma Completed NCT00773097 Phase 2
26 Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Completed NCT01187901 Phase 2 Erlotinib;Sulindac;Placebo A;Placebo B
27 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
28 Fatty Acid Desaturase Activity, Fish Oil and Colorectal Cancer Prevention Completed NCT01661764 Phase 2 Eicosapentanoic acid and docosahexanoic acid;Oleic Acid
29 Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer Recruiting NCT03796884 Phase 2 Linaclotide
30 Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention Recruiting NCT02965703 Phase 2 Aspirin
31 A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. The ASAMET Trial Recruiting NCT03047837 Phase 2 Aspirin (ASA) + Metformin (MET);ASA;MET;Placebos
32 PREPARE: PRevention Using EPA Against coloREctal Cancer Active, not recruiting NCT04216251 Phase 1, Phase 2 AMR101
33 Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas Active, not recruiting NCT02134925 Phase 2
34 PREPARE: PRevention Using EPA Against coloREctal Cancer Not yet recruiting NCT04172636 Phase 2 AMR101 (VASCEPA, icosapent ethyl)
35 Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer Terminated NCT01856322 Phase 2 Sulindac;Placebo
36 Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia Terminated NCT01606124 Phase 2 defined green tea catechin extract
37 Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses Withdrawn NCT03185871 Phase 2 Celecoxib
38 A Prospective Investigation of the ColubrisMX Endoluminal Surgical (ELS) System Active, not recruiting NCT04192565 Phase 1
39 Detection of Colorectal Adenomas in Côte-d'Or: Impact of Organized Screening on Socio-geographic Disparities Unknown status NCT02859714
40 Detection of Colorectal Adenoma by Optical Enhancement Technology vs. High-Definition Colonoscopy: A Randomized Trial Unknown status NCT02865382
41 Investigation of the Role of the Microbiome in the Pathogenesis of Colorectal Adenoma and Carcinoma Unknown status NCT02947607
42 Clinical Study That Effect of Individualized Intervention of Single Colonoscopy on Colorectal Adenomas Detection Unknown status NCT02693886
43 UKCAP Trial: A Multi-Center Double Blind Randomised Controlled Trial Of Aspirin And/Or Folate Supplementation For the Prevention Of Recurrent Colorectal Adenomas Unknown status NCT00033319 acetylsalicylic acid
44 Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique Unknown status NCT02935049
45 Prevalence of Colorectal Adenoma in 30- to 49-year-old Asymptomatic Subjects With a First Relative History of Colorectal Cancer Unknown status NCT01428752
46 Endoscopic Full Thickness Resection in the Lower GI Tract With the "Full Thickness Resection Device"- A Prospective Multicenter Trial Unknown status NCT02362126
47 Intubation Techniques on Colonoscopy Quality: A Single Center Randomized Control Clinical Trial Unknown status NCT01919463
48 Comparison of Detection and Miss Rates of Colorectal Adenoma by Blue Laser Imaging (BLI) Versus Conventional White Light Colonoscopy. Unknown status NCT02982447
49 A Pilot Study to Assess the Role for Endocuff© Assisted Colonoscopy in the Detection of Colonic Cancer and Polyps Unknown status NCT01761097
50 Efficacy of Segmental Re-examination and Retroflexion of Proximal Colon for Adenoma Miss Rate During Colonoscopy Unknown status NCT03355443

Search NIH Clinical Center for Colorectal Adenoma

Genetic Tests for Colorectal Adenoma

Genetic tests related to Colorectal Adenoma:

# Genetic test Affiliating Genes
1 Colorectal Adenoma 29

Anatomical Context for Colorectal Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Adenoma:

19
Colon, Rectum

MalaCards organs/tissues related to Colorectal Adenoma:

40
Colon, Testes, Liver, Prostate, T Cells, Breast, Endothelial

Publications for Colorectal Adenoma

Articles related to Colorectal Adenoma:

(show top 50) (show all 3819)
# Title Authors PMID Year
1
Effects of miR-135a-5p and miR-141 on proliferation, invasion and apoptosis of colorectal cancer SW620 cells. 61
32566020 2020
2
High Intake of Phenolic Acids Is Associated With Reduced Risk of Colorectal Adenomas Among Smokers. 61
31473361 2020
3
A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. 61
31776231 2020
4
Expression, Epigenetic, and Genetic Changes of HNF1B in Colorectal Lesions: an Analysis of 145 Cases. 61
32488808 2020
5
High risk of colorectal polyps in male with non-alcoholic fatty liver disease: a systematic review and meta-analysis. 61
32579269 2020
6
Chemoprevention in familial adenomatous polyposis: past, present and future. 61
32507936 2020
7
Genetic alteration of colorectal adenoma-carcinoma sequence among gastric adenocarcinoma and dysplastic lesions in a patient with attenuated familial adenomatous polyposis. 61
32543103 2020
8
Comprehensive RNA Sequencing in Adenoma-Cancer Transition Identified Predictive Biomarkers and Therapeutic Targets of Human CRC. 61
32145677 2020
9
SFRP1 promotor methylation analysis of FTA card touch-prep samples derived from colonic polyps. 61
32007530 2020
10
Association Between Carotid Ultrasonography Findings and Colorectal Adenoma in Asymptomatic Adults. 61
31624981 2020
11
Opportunistic use of radiological measures of visceral adiposity for assessment of risk of colorectal adenoma. 61
32501646 2020
12
Fecal DNA Testing of TWIST1 Methylation Identifies Patients With Advanced Colorectal Adenoma Missed by Fecal Immunochemical Test for Hemoglobin. 61
32467409 2020
13
Risk factors for metachronous colorectal cancer in Lynch syndrome patients: a registry-based observational mono-institutional study cohort. 61
32430733 2020
14
[Full thickness resection of a pyloric adenoma in the proximal duodenum in a 67-year-old patient with attenuated polyposis coli]. 61
32380553 2020
15
Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development. 61
32162306 2020
16
Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. 61
32475354 2020
17
The Influence of the Genetic and Immunologic Context in the Development of Colorectal Adenoma: A Case Series Report. 61
32416752 2020
18
Serum PIWI-Interacting RNAs piR-020619 and piR-020450 Are Promising Novel Biomarkers for Early Detection of Colorectal Cancer. 61
32066615 2020
19
Efficacy and safety of cold snare endoscopic mucosal resection for colorectal adenomas 10 to 14 mm in size: a prospective observational study. 61
32464143 2020
20
Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study. 61
31856598 2020
21
The relationship between the index of nutritional quality and the risk of colorectal cancer and adenoma : a case-control study. 61
32167962 2020
22
Colorectal Adenomas-Genetics and Searching for New Molecular Screening Biomarkers. 61
32380676 2020
23
Systematic Review of Prevalence, Risk Factors, and Risk for Metachronous Advanced Neoplasia in Patients With Young-Onset Colorectal Adenoma. 61
32428708 2020
24
Type 2 diabetes impacts colorectal adenoma detection in screening colonoscopy. 61
32385343 2020
25
Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases. 61
32428869 2020
26
Retrograde inspection vs standard forward view for the detection of colorectal adenomas during colonoscopy: A back-to-back randomized clinical trial. 61
32390706 2020
27
Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. 61
31926173 2020
28
KRAS mutation and abnormal expression of Cripto-1 as two potential candidate biomarkers for detection of colorectal cancer development. 61
31692030 2020
29
Efficacy of repeat forward-view examination of the right-sided colon during colonoscopy: A prospective randomized controlled trial. 61
32267568 2020
30
Regulatory and Policy-Related Aspects of Calcium Fortification of Foods. Implications for Implementing National Strategies of Calcium Fortification. 61
32276435 2020
31
Increased prevalence of Barrett's esophagus in patients with MUTYH-associated polyposis (MAP). 61
32088803 2020
32
Meta-analysis of 16S rRNA Microbial Data Identified Distinctive and Predictive Microbiota Dysbiosis in Colorectal Carcinoma Adjacent Tissue. 61
32291348 2020
33
Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study. 61
31981518 2020
34
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression. 61
31411736 2020
35
Genome-wide DNA methylation profiles of low- and high-grade adenoma reveals potential biomarkers for early detection of colorectal carcinoma. 61
32317010 2020
36
Skeletal muscle mass and risk of advanced adenoma in surveillance colonoscopy. 61
32350914 2020
37
ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment: implications for diseases progression and prognosis. 61
32246094 2020
38
Obesity is an initiator of colon adenomas but not a promoter of colorectal cancer in the Black Women's Health Study. 61
32124186 2020
39
Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis. 61
31695176 2020
40
Personal instruction for patients before colonoscopies could improve bowel preparation quality and increase detection of colorectal adenomas. 61
32233640 2020
41
Soy Metabolism by Gut Microbiota from Patients with Precancerous Intestinal Lesions. 61
32218321 2020
42
Effects of Genetic and Pharmacologic Inhibition of COX-2 on Colitis-associated Carcinogenesis in Mice. 61
32266177 2020
43
Global Prevalence of Colorectal Neoplasia: A Systematic Review and Meta-Analysis. 61
31323383 2020
44
The predictive value of small versus diminutive adenomas for subsequent advanced neoplasia. 61
31525360 2020
45
The association between colorectal cancer and prior antibiotic prescriptions: case control study. 61
31929515 2020
46
Should we invest in biological age predictors to treat colorectal cancer in older adults? 61
31761509 2020
47
[Analysis of DNA methylation alterations in cellfree DNA fraction during colorectal cancer development]. 61
32181765 2020
48
Detection of Colorectal Carcinoma Based on Microbiota Analysis Using Generalized Regression Neural Networks and Nonlinear Feature Selection. 61
30222584 2020
49
Proteome analysis of formalin-fixed paraffin-embedded colorectal adenomas reveals the heterogeneous nature of traditional serrated adenomas compared to other colorectal adenomas. 61
31729028 2020
50
Endocytoscopy for the differential diagnosis of colorectal low-grade adenoma: a novel possibility for the "resect and discard" strategy. 61
31785276 2020

Variations for Colorectal Adenoma

ClinVar genetic disease variations for Colorectal Adenoma:

6 (show all 13) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.3479C>A (p.Thr1160Lys)SNV Conflicting interpretations of pathogenicity 41503 rs201004111 5:112174770-112174770 5:112839073-112839073
2 APC NM_000038.6(APC):c.7717A>G (p.Ile2573Val)SNV Conflicting interpretations of pathogenicity 41536 rs145444830 5:112179008-112179008 5:112843311-112843311
3 APC NM_000038.6(APC):c.4360A>G (p.Lys1454Glu)SNV Conflicting interpretations of pathogenicity 127295 rs111866410 5:112175651-112175651 5:112839954-112839954
4 APC NM_000038.6(APC):c.4237A>G (p.Met1413Val)SNV Conflicting interpretations of pathogenicity 133510 rs141519952 5:112175528-112175528 5:112839831-112839831
5 APC NM_000038.6(APC):c.6985A>G (p.Ile2329Val)SNV Conflicting interpretations of pathogenicity 135716 rs146048493 5:112178276-112178276 5:112842579-112842579
6 APC NM_000038.6(APC):c.8266A>G (p.Ile2756Val)SNV Conflicting interpretations of pathogenicity 135724 rs146115809 5:112179557-112179557 5:112843860-112843860
7 APC NM_000038.6(APC):c.4732T>G (p.Cys1578Gly)SNV Conflicting interpretations of pathogenicity 140839 rs138367627 5:112176023-112176023 5:112840326-112840326
8 APC NM_000038.6(APC):c.8383G>A (p.Ala2795Thr)SNV Conflicting interpretations of pathogenicity 141047 rs369264968 5:112179674-112179674 5:112843977-112843977
9 APC NM_000038.6(APC):c.2847G>T (p.Met949Ile)SNV Conflicting interpretations of pathogenicity 161206 rs147394539 5:112174138-112174138 5:112838441-112838441
10 APC NM_000038.6(APC):c.7778A>G (p.Asn2593Ser)SNV Conflicting interpretations of pathogenicity 161205 rs367676584 5:112179069-112179069 5:112843372-112843372
11 APC NM_000038.6(APC):c.449A>G (p.Lys150Arg)SNV Uncertain significance 141928 rs371085910 5:112111352-112111352 5:112775655-112775655
12 APC NM_000038.6(APC):c.4420G>A (p.Ala1474Thr)SNV Benign/Likely benign 133530 rs139387758 5:112175711-112175711 5:112840014-112840014
13 APC NM_000038.6(APC):c.4336G>A (p.Ala1446Thr)SNV Benign/Likely benign 127294 rs146572883 5:112175627-112175627 5:112839930-112839930

Expression for Colorectal Adenoma

LifeMap Discovery
Genes differentially expressed in tissues of Colorectal Adenoma patients vs. healthy controls: 35 (show top 50) (show all 255)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GCG glucagon Colon - 9.14 0.000
2 GUCA2B guanylate cyclase activator 2B (uroguanylin) Colon - 8.78 0.000
3 MS4A12 membrane-spanning 4-domains, subfamily A, member 12 Colon - 8.78 0.000
4 AQP8 aquaporin 8 Colon - 8.30 0.000
5 CA1 carbonic anhydrase I Colon - 8.11 0.000
6 CLCA4 chloride channel accessory 4 Colon - 7.63 0.000
7 CA4 carbonic anhydrase IV Colon - 7.51 0.000
8 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) Colon + 7.34 0.000
9 CLDN8 claudin 8 Colon - 7.18 0.000
10 CDH3 cadherin 3, type 1, P-cadherin (placental) Colon + 6.97 0.000
11 GUCA2A guanylate cyclase activator 2A (guanylin) Colon - 6.92 0.000
12 HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 Colon - 6.85 0.001
13 PRAC1 prostate cancer susceptibility candidate 1 Colon - 6.72 0.040
14 CEMIP cell migration inducing protein, hyaluronan binding Colon + 6.69 0.000
15 INSL5 insulin-like 5 Colon - 6.67 0.000
16 PYY peptide YY Colon - 6.57 0.000
17 SCNN1B sodium channel, non voltage gated 1 beta subunit Colon - 6.53 0.000
18 CHGA chromogranin A Colon - 6.30 0.000
19 SST somatostatin Colon - 5.99 0.000
20 ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) Colon - 5.77 0.002
21 SLC51B solute carrier family 51, beta subunit Colon - 5.54 0.001
22 CD177 CD177 molecule Colon - 5.52 0.003
23 GCNT2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) Colon - 5.48 0.000
24 SLC25A34 solute carrier family 25, member 34 Colon - 5.43 0.000
25 SLC26A3 solute carrier family 26 (anion exchanger), member 3 Colon - 5.39 0.002
26 CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) Colon - 5.35 0.000
27 ZG16 zymogen granule protein 16 Colon - 5.34 0.000
28 MSX2 msh homeobox 2 Colon + 5.31 0.000
29 FABP6 fatty acid binding protein 6, ileal Colon + 5.29 0.000
30 EPHX4 epoxide hydrolase 4 Colon + 5.24 0.000
31 DUSP27 dual specificity phosphatase 27 (putative) Colon + 5.23 0.000
32 TACSTD2 tumor-associated calcium signal transducer 2 Colon + 5.10 0.000
33 GABRP gamma-aminobutyric acid (GABA) A receptor, pi Colon + 5.08 0.003
34 BEST4 bestrophin 4 Colon - 5.08 0.001
35 S100A2 S100 calcium binding protein A2 Colon + 5.05 0.000
36 DPEP1 dipeptidase 1 (renal) Colon + 5.04 0.010
37 MUC12 mucin 12, cell surface associated Colon - 4.98 0.020
38 SPINK5 serine peptidase inhibitor, Kazal type 5 Colon - 4.96 0.001
39 PCSK1 proprotein convertase subtilisin/kexin type 1 Colon + 4.92 0.008
40 SLC30A10 solute carrier family 30, member 10 Colon - 4.89 0.003
41 TMEM72 transmembrane protein 72 Colon - 4.88 0.000
42 KLK10 kallikrein-related peptidase 10 Colon + 4.85 0.020
43 CDH19 cadherin 19, type 2 Colon - 4.83 0.001
44 CDKN2B-AS1 CDKN2B antisense RNA 1 Colon - 4.75 0.004
45 MT1M metallothionein 1M Colon - 4.75 0.027
46 SLC6A19 solute carrier family 6 (neutral amino acid transporter), member 19 Colon - 4.71 0.007
47 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) Colon - 4.70 0.000
48 ANO5 anoctamin 5 Colon - 4.68 0.000
49 FOXQ1 forkhead box Q1 Colon + 4.62 0.000
50 CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7 Colon - 4.60 0.001
Search GEO for disease gene expression data for Colorectal Adenoma.

Pathways for Colorectal Adenoma

Pathways related to Colorectal Adenoma according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 TP53 PTGS2 MYC KRAS IGF1 HRAS
2
Show member pathways
13 TP53 KRAS IGF1 HRAS CTNNB1 CDH1
3
Show member pathways
12.98 TP53 PTGS2 MYC KRAS IGF1 HRAS
4
Show member pathways
12.96 TP53 PTGS2 MYC KRAS HRAS CTNNB1
5
Show member pathways
12.94 TP53 PTGS2 MSH2 MLH1 KRAS HRAS
6 12.79 TP53 MYC KRAS IGF1 HRAS
7
Show member pathways
12.77 TP53 MYC MSH2 MLH1 KRAS IGF1
8
Show member pathways
12.76 KRAS IGF1 HRAS CTNNB1 CDH1
9
Show member pathways
12.73 TP53 MYC KRAS IGF1 HRAS
10
Show member pathways
12.72 TP53 MYC MLH1 KRAS IGF1 HRAS
11
Show member pathways
12.71 TP53 PTGS2 KRAS HRAS CTNNB1 CDH1
12
Show member pathways
12.7 TP53 KRAS IGF1 HRAS CDH1
13
Show member pathways
12.65 TP53 MYC KRAS IGF1 HRAS
14
Show member pathways
12.62 TP53 MYC MSH2 KRAS HRAS CTNNB1
15
Show member pathways
12.53 TP53 MYC KRAS HRAS CTNNB1 CDH1
16
Show member pathways
12.52 TP53 KRAS IGF1 HRAS APC
17 12.45 TP53 PTGS2 MYC CTNNB1 CDH1 APC
18
Show member pathways
12.42 PTGS2 KRAS HRAS CTNNB1
19
Show member pathways
12.42 KRAS IGF1 HRAS CTNNB1 CDH1 APC
20
Show member pathways
12.42 TP53 MYC IGFBP3 IGF1 HRAS
21 12.42 TP53 PTGS2 MYC MSH2 MLH1 KRAS
22
Show member pathways
12.4 TP53 MYC MIR17 IGFBP3 IGF1
23 12.39 TP53 MYC CDH1 APC
24 12.37 TP53 MYC KRAS HRAS
25
Show member pathways
12.35 TP53 IGF1 HRAS CTNNB1 APC
26
Show member pathways
12.35 MYC KRAS HRAS CTNNB1 CDH1
27 12.3 TP53 MYC IGFBP3 IGF1
28 12.3 TP53 PTGS2 MYC MIR21 MIR17 MIR15A
29 12.29 TP53 MYC MIR21 KRAS IGF1 HRAS
30
Show member pathways
12.26 TP53 MYC CTNNB1 APC
31 12.2 TP53 MYC KRAS IGFBP3 HRAS
32 12.18 MYC CTNNB1 CDH1 APC
33
Show member pathways
12.16 TP53 MYC KRAS HRAS
34
Show member pathways
12.15 TP53 KRAS IGF1 HRAS
35 12.13 MYC KRAS IGF1 HRAS CTNNB1 APC
36 12.1 TP53 ODC1 MYC MSH2 KRAS CTNNB1
37 12.07 VDR TP53 MSH2 MLH1 IGFBP3 APC
38 12.06 KRAS HRAS CTNNB1 CDH1 APC
39 12.04 TP53 MYC KRAS HRAS CTNNB1
40 11.99 TP53 MYC KRAS HRAS CTNNB1 APC
41 11.98 TP53 IGFBP3 IGF1 HRAS
42 11.85 TP53 MYC KRAS IGF1 HRAS CTNNB1
43 11.82 TP53 ODC1 MYC
44 11.82 MYC CTNNB1 CDH1 APC
45 11.77 TP53 MSH2 MLH1
46 11.77 TP53 MYC KRAS HRAS CDH1
47 11.76 TP53 MYC KRAS HRAS
48 11.73 TP53 KRAS HRAS
49 11.73 MYC CTNNB1 APC
50 11.72 TP53 MYC HRAS

GO Terms for Colorectal Adenoma

Cellular components related to Colorectal Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral plasma membrane GO:0016328 9.43 CTNNB1 CDH1 APC
2 flotillin complex GO:0016600 9.32 CTNNB1 CDH1
3 insulin-like growth factor ternary complex GO:0042567 9.16 IGFBP3 IGF1
4 insulin-like growth factor binding protein complex GO:0016942 8.96 IGFBP3 IGF1
5 catenin complex GO:0016342 8.8 CTNNB1 CDH1 APC

Biological processes related to Colorectal Adenoma according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 VDR TP53 MYC IGF1 HRAS GREM1
2 positive regulation of transcription, DNA-templated GO:0045893 10.04 TP53 MYC IGF1 GREM1 CTNNB1 CDH1
3 negative regulation of apoptotic process GO:0043066 10 TP53 PTGS2 MYC MIR21 IGF1 GREM1
4 cellular response to DNA damage stimulus GO:0006974 9.99 TP53 MYC MUTYH MSH2 MLH1 APC
5 positive regulation of cell migration GO:0030335 9.97 MIR21 IGF1 HRAS APC
6 in utero embryonic development GO:0001701 9.96 TP53 MYC MSH2 CTNNB1
7 response to drug GO:0042493 9.91 TP53 PTGS2 MYC MTHFR CTNNB1 CDH1
8 positive regulation of apoptotic process GO:0043065 9.87 TP53 PTGS2 MIR21 MIR15A IGFBP3 CTNNB1
9 cellular response to hypoxia GO:0071456 9.86 TP53 PTGS2 MYC MIR17
10 positive regulation of gene expression GO:0010628 9.86 VDR TP53 MYC MIR21 KRAS IGF1
11 positive regulation of MAPK cascade GO:0043410 9.84 IGFBP3 IGF1 HRAS CTNNB1
12 positive regulation of epithelial cell proliferation GO:0050679 9.81 MYC IGF1 HRAS
13 positive regulation of osteoblast differentiation GO:0045669 9.81 MIR21 IGF1 CTNNB1
14 positive regulation of cell proliferation GO:0008284 9.81 PTGS2 ODC1 MYC MIR21 KRAS IGF1
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 PTGS2 MYC IGF1
16 cell cycle arrest GO:0007050 9.8 TP53 MYC MSH2 HRAS APC
17 cellular response to UV GO:0034644 9.79 TP53 PTGS2 MYC
18 positive regulation of fibroblast proliferation GO:0048146 9.79 MYC MIR17 IGF1
19 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.78 MIR21 MIR17 IGF1
20 Ras protein signal transduction GO:0007265 9.78 TP53 KRAS IGF1 HRAS
21 positive regulation of telomerase activity GO:0051973 9.72 MYC GREM1 CTNNB1
22 mismatch repair GO:0006298 9.7 MUTYH MSH2 MLH1
23 ovulation GO:0030728 9.67 PTGS2 MYC
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.67 MSH2 MLH1
25 positive regulation of metalloendopeptidase activity GO:1904685 9.66 MIR21 MIR17
26 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.65 MIR21 IGF1
27 endothelial tube morphogenesis GO:0061154 9.65 MIR21 CTNNB1
28 entry of bacterium into host cell GO:0035635 9.64 CTNNB1 CDH1
29 response to isolation stress GO:0035900 9.62 KRAS HRAS
30 signal transduction by p53 class mediator GO:0072331 9.6 TP53 GREM1
31 cellular response to indole-3-methanol GO:0071681 9.59 CTNNB1 CDH1
32 positive regulation of isotype switching to IgA isotypes GO:0048298 9.58 MSH2 MLH1
33 somatic recombination of immunoglobulin gene segments GO:0016447 9.58 MSH2 MLH1
34 negative regulation of gene expression GO:0010629 9.56 VDR TP53 MYC MIR21 MIR17 IGF1
35 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR21 MIR17 IGF1
36 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.49 MSH2 MLH1
37 negative regulation of cell proliferation GO:0008285 9.28 VDR TP53 PTGS2 MIR21 MIR15A IGFBP3

Molecular functions related to Colorectal Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.35 TP53 PTGS2 MSH2 MLH1 CTNNB1
2 MutSalpha complex binding GO:0032407 9.32 MUTYH MLH1
3 MutLalpha complex binding GO:0032405 9.26 MUTYH MSH2
4 oxidized purine DNA binding GO:0032357 9.16 MUTYH MSH2
5 guanine/thymine mispair binding GO:0032137 8.62 MSH2 MLH1

Sources for Colorectal Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....